Fluconazole response patterns in HIV-infected patients with oropharyngeal candidiasis.
A prospective study to assess the efficacy of fluconazole in oropharyngeal candidiasis in patients with HIV was conducted. A cohort of 30 HIV-positive persons with clinical and microbiologic confirmed oropharyngeal candidiasis (Candida albicans > 1000 CFU/ml) received fluconazole 100 mg daily for 7 days. In vitro antifungal susceptibility tests demonstrated a lack of fluconazole resistances. Cultures of mouth swabs were performed at the end of therapy and 2 weeks later. There was a clinical and microbiologic cure in 26 patients (87%). In 10 of these 26, cultures remained negative after 2 weeks; most of them had CD4 lymphocyte count > 400/ml. In the other 16 patients (53%), cultures showed a microbiologic relapse 2 weeks after treatment. In spite of clinical improvement, treatment failure was observed in four patients, all of them with CD4 lymphocyte count < 50 ml.
Diz Dios
P D
PD
Section for Special Patients, School of Dentistry, Santiago de Compostela University, Spain.
Alvarez Alvarez
J
J
Fernández Feijoo
J
J
Castro Ferreiro
M
M
D018791:CD4 Lymphocyte Count; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000209:etiology; D015169:Colony Count, Microbial; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
D015725:Fluconazole